[ 123I]Epidepride neuroimaging of dopamine D 2/D 3 receptor in chronic MK-801-induced rat schizophrenia model

Nuclear Medicine and Biology

Volumn 39, Issue 6, 2012, Pages 826-832

  Huang, Yuan Ruei ^a   Shih, Jun Ming ^a   Chang, Kang Wei ^a   Huang, Chieh ^a   Wu, Yu Lung ^a   Chen, Chia Chieh ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Dopamine D 2 D 3 receptor; Epidepride; Midbrain; MK 801; Schizophrenia; Striatum

Indexed keywords

DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE I 123; SODIUM CHLORIDE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DIZOCILPINE MALEATE; EPIDEPRIDE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; EX VIVO STUDY; HYPOTHALAMUS; MALE; MESENCEPHALON; MOTOR ACTIVITY; NEUROIMAGING; NONHUMAN; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL INTERACTION; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE MODEL; DRUG EFFECT; METABOLISM; METHODOLOGY; NEOSTRIATUM; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; IODINE RADIOISOTOPES; MALE; NEOSTRIATUM; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TYROSINE 3-MONOOXYGENASE;

EID: 84863992374     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.005     Document Type: Article

References (46)

1. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
2. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996, 93:9235-9240.
3. Weinberger D.R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
4. Reith J., Benkenfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994, 91:11651-11654.
5. Finlay J.M. Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr Bull 2001, 27:431-442.
6. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
7. Cook C.D., Newman J.L., Winfree J.C., Beardsley P.M. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Pharmacol Biochem Behav 2004, 77:309-318.
8. Kalinichev M., Robbins M.J., Hartfield E.M., Maycox P.R., Moore S.H., Savage K.M., et al. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:414-422.
9. Rung J.P., Carlsson A., Rydén Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:827-832.
10. Bubeníková-Valesová V., Horácek J., Vrajová M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008, 32:1014-1023.
11. Marcus M.M., Mathe J.M., Nomikos G.G., Svensson T.H. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology 2001, 40:482-490.
12. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
13. Bubeníková V., Votava M., Horácek J., Pálenícek T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005, 80:591-596.
14. 2 dopamine receptors in the temporal lobe in schizophrenia. Arch Gen Psychiatry 1997, 54:649-658.
15. Akil M., Pierri J.N., Whitehead R.E., Edgar C.L., Mohila C., Sampson A.R., et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999, 156:1580-1589.
16. Young K.A., Manaye K.F., Liang C.L., Hicks P.B., German D.C. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000, 47:944-953.
17. 3 receptor binding in drug-naïve patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003, 6:361-370.
18. 2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 2006, 148:165-173.
19. 3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003, 8:453-455.
20. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
21. 3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci 2009, 63:529-537.
22. Tuppurainen H., Kuikka J.T., Viinamäki H., Husso M., Tiihonen J. Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra. Nord J Psychiatry 2010, 64:233-238.
23. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect 1993, 91:13-25.
24. Hadjiconstantinou M., Rossetti Z.L., Wemlinger T.A., Neff N.H. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic l-amino acid decarboxylase activity. Eur J Pharmacol 1995, 289:97-101.
25. Biggs C.S., Fowler L.J., Whitton P.S., Starr M.S. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats. Eur J Pharmacol 1996, 299:83-91.
26. Mathé J.M., Nomikos G.G., Blakeman K.H., Svensson T.H. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 1999, 38:121-128.
27. Engberg G., Kling-Petersen T., Nissbrandt H. GABAB-receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse 1993, 15:229-238.
28. Van Bockstaele E.J., Pickel V.M. GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res 1995, 682:215-221.
29. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002, 59:25-30.
30. 3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003, 8:453-455.
31. Shergill S.S., Brammer M.J., Williams S.C., Murray R.M., McGuire P.K. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000, 57:1033-1038.
32. 3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006, 256:382-387.
33. 2 dopamine receptor function in rat striatum. Pharmacol Biochem Behav 1993, 44:683-687.
34. Meador-Woodruff J.H., Damask S.P., Watson S.J. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci U S A 1994, 91:8297-8301.
35. Meador-Woodruff J.H., Damask S.P., Wang J., Haroutunian V., Davis K.L., Watson S.J. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsycho-pharmacology 1996, 15:17-29.
36. Martín-Ruiz R., Ugedo L., Honrubia M.A., Mengod G., Artigas F. Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. Neurochem 2001, 77:762-775.
37. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999, 72:148-156.
38. 2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A 1991, 88:1859-1863.
39. 2 dopamine receptor mRNA subtypes in rat brain. Neurochem Int 1992, 20:49S-58S.
40. Kang D.H., Kwon K.W., Gu B.M., Choi J.S., Jang J.H., Kwon J.S. Structural abnormalities of the right inferior colliculus in schizophrenia. Psychiatry Res 2008, 164:160-165.
41. Koolschijn P.C., van Haren N.E., Hulshoff Pol H.E., Kahn R.S. Hypothalamus volume in twin pairs discordant for schizophrenia. Eur Neuropsychopharmacol 2008, 18:312-315.
42. Goldstein J.M., Seidman L.J., Makris N., Ahern T., O'Brien L.M., Caviness V.S., et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry 2007, 61:935-945.
43. Klomp A., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S., Van Haren N.E. Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. Int J Neuropsychopharmacol 2011, 1-8.
44. Abe H., Rusak B., Robertson H.A. Photic induction of Fos protein in the suprachiasmatic nucleus is inhibited by the NMDA receptor antagonist MK-801. Neurosci Lett 1991, 127:9-12.
45. 2C agonist on melatonin rhythmicity and c-fos induction in the suprachiasmatic nucleus. Brain Res 1999, 845:102-106.
46. Umryukhin P.E., Anokhin K.V., Raevskii K.S. Dizocilpine blocks the effects of delta sleep-inducing peptide-induced suppression of c-fos gene expression in the paraventricular nucleus of the hypothalamus in rats. Neurosci Behav Physiol 2004, 34:501-503.